PROCEPT BioRobotics Corporation - Common Stock (PRCT)
61.44
-2.91 (-4.52%)
Procept Biorobotics Corp is a medical technology company focused on advancing minimally invasive surgical solutions, particularly for the treatment of benign prostate hyperplasia
The company develops innovative robotic-assisted platforms that enhance the precision and effectiveness of procedures, empowering urologists to deliver better patient outcomes while reducing recovery times. Procept aims to transform standard surgical practices through its cutting-edge technology, improving the overall experience for both patients and healthcare providers.

Via Benzinga · February 26, 2025

Spruce Point Capital warns of Procept BioRobotics' overstated market potential and growth claims, citing niche product limitations and valuation risks.
Via Benzinga · January 16, 2025

Morgan Stanley upgrades key MedTech stocks, highlighting strong demand and growth potential, while downgrading others amid company-specific challenges.
Via Benzinga · December 2, 2024

Via Benzinga · December 2, 2024

Via Benzinga · November 14, 2024

Via Benzinga · December 2, 2024

Top mid-cap stock performers: MDGL (+51.70%), PRCT (+34.20%), GSAT (+33.98%), WGS (+31.17%), NXT (+25.91%), VFC (+25.82%), OMCL (+23.22%).
Via Benzinga · November 3, 2024

Royal Caribbean earns its spot on the Big Cap 20 with a best-possible 99 Composite Rating, putting it in the top 1% of all stocks.
Via Investor's Business Daily · October 28, 2024

PROCEPT BioRobotics stock gains as Q3 earnings beat estimates with revenue up 66% YoY, driven by strong system sales and consumable revenue growth.
Via Benzinga · October 28, 2024

Via Benzinga · October 28, 2024

The company sells systems that perform aquablation to treat enlarged prostates.
Via Investor's Business Daily · October 28, 2024

Jim Cramer discusses PROCEPT BioRobotics, Zoetis, Target and Consolidated Edison. "
Via Benzinga · September 4, 2024

Via Benzinga · August 25, 2024

Via Benzinga · August 21, 2024

Via Benzinga · August 2, 2024

Discover which robotics stocks to sell in August and why, ensuring you avoid potential market downturns and secure your investments.
Via InvestorPlace · August 14, 2024